A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week)

Abstract

Here we present a 45-year-old male patient who suffered from psoriatic arthritis (PsA), for which adalimumab (80 mg every other week) was effective. Dose escalation of a TNF-α antagonist should be considered for patients showing an inadequate response for disease stabilization in PsA.

Keywords

• Psoriatic arthritis
• biologic
• adalimumab
• psoriasis